Bookmark

Add to MyYahoo RSS

Shire plc News

News on Shire plc (Ticker: SHPGY) continually updated from thousands of sources around the net.

Tuesday | AmericanBankingNews.com

Shire PLC

Shire PLC opened at 151.35 on Tuesday. Shire PLC has a one year low of $86.01 and a one year high of $172.27.

Comment?

Related Topix: Biotech

Mon Apr 21, 2014

Bloomberg

Pfizer, AstraZeneca Are Ripe for Pharma Deal

While the talks between Pfizer, the world's biggest drugmaker, and $87 billion AstraZeneca have fizzled, Citigroup Inc. expects Pfizer to approach the company again, or AstraZeneca could opt to merge with another peer such as Amgen Inc. as a defense tactic.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Banking, Financial Services, Citigroup, Amgen, Cancer, Health

Thu Apr 17, 2014

Hispanic Business

Pre-quarterly Results Communication

Foreign Exchange Average exchange rates for Q1 2014 were . Foreign exchange is not expected to have a material effect on revenues in Shire's Q1 2014 results.

Comment?

Related Topix: Biotech, Financial Markets, ViroPharma, Medicine, Healthcare Industry

Mon Apr 14, 2014

The Washington Post

Novartis to Shire Said to Consider Bidding for ThromboGenics

Novartis AG and Shire Plc are among drugmakers weighing offers for Belgian eye-medicine company ThromboGenics NV, people familiar with the matter said.

Comment?

Related Topix: Biotech, Noven Pharmaceuticals, Genetics, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Allergan, Tarrytown, NY

AmericanBankingNews.com

Shire PLC Receives "Overweight" Rating from Barclays

's stock had its "overweight" rating restated by Barclays in a research note issued on Monday, AnalystRatingsNetwork reports.

Comment?

Related Topix: Biotech

Sun Apr 13, 2014

Bloomberg

Deadly Bowel Infection Draws Drugmakers Seeking Cures

Drugmakers led by Merck & Co. and Sanofi are searching for new weapons against a deadly bacteria implicated in hospital and nursing-home infections.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry

Tue Apr 01, 2014

AmericanBankingNews.com

Shire PLC Rating Reiterated by Goldman Sachs

's stock had its "strong-buy" rating reiterated by equities researchers at Goldman Sachs in a research report issued on Tuesday, AnalystRatings.Net reports.

Comment?

Related Topix: Biotech

Mon Mar 31, 2014

PR-inside.com

Shire Plc: Pharmaceuticals and Healthcare - Company Profile, SWOT and ...

The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company history, financial analysis, mergers and acquisitions, recent developments, key employees, company locations and subsidiaries, employee biographies as well as competitive benchmarking data.

Comment?

Related Topix: Biotech

Fri Mar 28, 2014

AmericanBankingNews.com

Shire PLC Given Outperform Rating at BNP Paribas

's stock had its "outperform" rating restated by research analysts at BNP Paribas in a report released on Friday, Stock Ratings News reports.

Comment?

Related Topix: Biotech, Banking, JP Morgan Chase

Thu Mar 27, 2014

BioSpace

Shire Submits INTUNIV (Guanfacine Extended Release) Marketing...

March 27, 2014 - Shire plc today announced the acceptance of submission of a Marketing Authorisation Application by the European Medicines Agency for their once-daily, non-stimulant guanfacine extended release for the treatment of Attention Deficit/Hyperactivity Disorder in children/adolescents aged 6-17 years.

Comment?

Related Topix: Biotech, Marketing, ADHD, Health

Wed Mar 26, 2014

The Motley Fool

Will Shire PLC Build Or Buy Its Future?

The ideal in the biotech and pharma world may be for a company to develop a strong internal R&D engine that regularly churns out potential blockbuster compounds, but the reality is that most companies have to turn to partnerships and acquisitions to manage risk and maintain growth.

Comment?

Related Topix: Biotech, Medicine, ADHD, Health, Marketing

Tue Mar 25, 2014

AmericanBankingNews.com

Shire PLC PT Raised to $173.00 at JPMorgan Chase & Co.

JPMorgan Chase & Co.' s target price would indicate a potential upside of 17.22% from the stock's previous close.

Comment?

Related Topix: Biotech, Banking, JP Morgan Chase

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••